Trial · NCT02291289
Participant flow143
How many started, completed or left each group, period by period.
1 to 20 of 143
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Induction Treatment | STARTED | Cohort 1: Induction Phase (IP) | 93 | |
| Induction Treatment | STARTED | Cohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,Vemurafenib | 0 | |
| Induction Treatment | STARTED | Cohort 1 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | 0 | |
| Induction Treatment | STARTED | Cohort 2 (IP) | 635 | |
| Induction Treatment | STARTED | Cohort 2 (MP):5-FU/LV or Capecitabine,Bevacizumab,Atezolizumab | 0 | |
| Induction Treatment | STARTED | Cohort 2 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | 0 | |
| Induction Treatment | STARTED | Cohort 3 (IP) | 6 | |
| Induction Treatment | STARTED | Cohort 3 (MP): Capecitabine,Trastuzumab,Pertuzumab | 0 | |
| Induction Treatment | STARTED | Cohort 3 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | 0 | |
| Induction Treatment | STARTED | Cohort 4 (IP) | 310 | |
| Induction Treatment | STARTED | Cohort 4 (MP): Cobimetinib,Atezolizumab | 0 | |
| Induction Treatment | STARTED | Cohort 4 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | 0 | |
| Induction Treatment | STARTED | Early Progressing BRAFmut Cohort | 0 | |
| Induction Treatment | Treated During Induction Phase | Cohort 1: Induction Phase (IP) | 93 | |
| Induction Treatment | Treated During Induction Phase | Cohort 1 (Maintenance Phase[MP]):5-FU/LV,Cetuximab,Vemurafenib | 0 | |
| Induction Treatment | Treated During Induction Phase | Cohort 1 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | 0 | |
| Induction Treatment | Treated During Induction Phase | Cohort 2 (IP) | 632 | |
| Induction Treatment | Treated During Induction Phase | Cohort 2 (MP):5-FU/LV or Capecitabine,Bevacizumab,Atezolizumab | 0 | |
| Induction Treatment | Treated During Induction Phase | Cohort 2 Control (MP): 5-FU/LV or Capecitabin, Bevacizumab | 0 | |
| Induction Treatment | Treated During Induction Phase | Cohort 3 (IP) | 6 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02291289/flow